IMAC Holdings, Inc. Share Price

Equities

BACK

US44967K3023

Healthcare Facilities & Services

Market Closed - Nasdaq 01:30:00 27/04/2024 am IST 5-day change 1st Jan Change
3.92 USD -23.14% Intraday chart for IMAC Holdings, Inc. +24.84% +77.38%
Sales 2024 * - Sales 2025 * - Capitalization 4.5M 375M
Net income 2024 * -4M -334M Net income 2025 * -4M -334M EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-1.08 x
P/E ratio 2025 *
-1.08 x
Employees 3
Yield 2024 *
-
Yield 2025 *
-
Free-Float 82.64%
More Fundamentals * Assessed data
Dynamic Chart
IMAC Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
IMAC Holdings, Inc. announced that it expects to receive $0.9 million in funding from District 2 Capital LP, Ashton Capital Corporation, Cavalry Fund I Management, LLC, Kips Bay Select LP, Walleye Capital LLC, Lincoln Park Capital, LLC CI
Top Premarket Decliners MT
IPM Medical Group, Inc. acquired IMAC Regeneration Center in Arlington Heights, Illinois from IMAC Holdings, Inc.. CI
IMAC Holdings, Inc. Announces Executive Changes CI
The Regenerative Center, LLC acquired Tangible and intangible assets of Kentucky operation of IMAC Holdings, Inc. for $0.08 million. CI
IMAC Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
IMAC Holdings Regains Compliance With Nasdaq Listing Rule MT
Labor Data, Inflation Woes Weigh on Exchange-Traded Funds, Equity Futures Premarket Friday MT
IMAC Holdings Implements 1-for-30 Reverse Stock Split MT
IMAC Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
IMAC Holdings, Inc. announced that it has received $4.3 million in funding from Theralink Technologies, Inc. and other investors CI
IMAC, Theralink Technologies Sign Merger Deal; IMAC Shares Jump MT
IMAC Holdings, Inc. Appoints Jeffrey Busch to Serve as Chairman CI
IMAC Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
More news
1 day-23.14%
1 week+24.84%
Current month+28.10%
1 month+28.10%
3 months+85.78%
6 months+108.58%
Current year+77.38%
More quotes
1 week
3.00
Extreme 3
7.75
1 month
2.40
Extreme 2.4001
7.75
Current year
1.22
Extreme 1.2176
7.75
1 year
1.22
Extreme 1.2176
7.75
3 years
1.22
Extreme 1.2176
82.50
5 years
1.22
Extreme 1.2176
165.00
10 years
1.22
Extreme 1.2176
216.15
More quotes
Managers TitleAgeSince
Chief Executive Officer 46 01/15/01
Founder 50 01/00/01
Director of Finance/CFO 55 01/17/01
Members of the board TitleAgeSince
Director/Board Member 64 21/20/21
Director/Board Member 71 21/20/21
Chief Executive Officer 46 01/15/01
More insiders
Date Price Change Volume
26/24/26 3.92 -23.14% 831,337
25/24/25 5.1 +46.34% 8,489,198
24/24/24 3.485 +5.61% 164,366
23/24/23 3.3 +6.80% 118,878
22/24/22 3.09 -1.59% 37,565

Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST

More quotes
IMAC Holdings, Inc. owns and manages health and wellness centers that delivers sports medicine, orthopedic care, and restorative joint and tissue therapies for movement restricting pain and neurodegenerative diseases. The Company provides movement, orthopedic and neurological therapies through its chain of Innovative Medical Advancements and Care (IMAC) Regeneration Centers. The Company, through its outpatient medical clinics, provide conservative, minimally invasive medical treatments to help patients with back pain, knee pain, joint pain, ligament and tendon damage, and other related soft tissue conditions. It operates through two business segments: outpatient medical centers and clinical research division. The Company's research division is conducting a Phase I clinical trial evaluating a mesenchymal stem cell therapy candidate for bradykinesia due to Parkinson’s disease. The Company operates approximately 10 outpatient medical clinics in five states in the United States.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.92 USD
Average target price
8 USD
Spread / Average Target
+104.08%
Consensus